QuidelOrtho Corp (QDEL) stock intrinsic value fair value estimate & owner earnings analysis

QuidelOrtho makes diagnostic tests. Its Labs business (about $1.5 billion of 2025 revenue) sells instruments and the reagents and consumables they run on to hospital and reference laboratories; Immunohematology (about $0.54 billion) supplies blood-typing products; Point of Care (about $0.6 billion) sells rapid tests such as QuickVue and Sofia, historically driven by COVID and flu demand. Most instruments are placed with customers under a reagent rental model: the company keeps the instrument and recovers its cost through multi-year minimum purchases of tests. That gives the Labs and Immunohematology franchises real staying power, but it also means a steady stream of cash goes into building instruments. That cost passes through inventory in the cash flow statement rather than showing up as capital spending. What we measure. Revenue has fallen three years running ($3.27 billion in 2022, $3.00 billion in 2023, $2.78 billion in 2024, $2.73 billion in 2025) as COVID testing normalised and the US donor screening business was wound down. Cash from operations was $280 million, $83 million and $105 million in 2023 to 2025. We strip out true timing swings in receivables, payables, taxes and accruals. We do not strip out the inventory outflow that becomes leased instruments: inventory on the balance sheet barely moved ($524 million to $578 million over three years) while cash outflows for inventory totalled about $494 million, and customer-leased instruments in property and equipment rose from $728 million to $906 million in 2025 alone. Treating that as timing would flatter earnings. After stock compensation ($42 to $52 million a year) and capital spending ($188 to $209 million), owner earnings were about $0.84 per share in 2023, negative $2.58 in 2024 and negative $1.59 in 2025. The company then pays lenders roughly $150 to $177 million of cash interest a year. Before interest, the business generated about $3.09, $0.06 and $0.96 per share in those three years. Our starting level is the middle of those three years, $0.96 per share. We start in 2023 because the May 2022 merger with Ortho created a different company; 2022 is a partial year at the COVID peak. Debt comes first. In August 2025 the company refinanced into a $1.15 billion Term Loan A (effective rate 6.87% at year-end, due 2030), a $1.45 billion Term Loan B (8.43%, due 2032) and a $700 million revolver, secured on substantially all assets, with covenants of maximum leverage of 4.5 times and minimum interest cover of 3.0 times. By June 2026 total debt had risen to about $2.9 billion (about $2.94 billion of principal) against $123 million of cash, partly to fund a $97 million acquisition payment in the first half of 2026 (we take this to be the LEX Diagnostics deal announced in June 2025) and a first-half operating cash outflow of $144 million. Net debt is about $2.8 billion, or $41 per share. Because much of it costs more than 6% for years, we add about $2.80 per share; the bear case adds about $4.50 given the tighter covenants. Total obligations are $44 per share in the base and bull cases and $45.70 in the bear case. Base case (about negative $27 per share). Business cash flow starts at $0.50 per share in 2026, reflecting a weak first half of 2026 (revenue down 4%, operating losses in both quarters), climbs to $0.75 and then back to the $0.96 normal level by 2028 as the roughly $100 million restructuring programme runs off (planned through 2027), then grows 2% a year through 2035 and stays flat after that. The 2% is below the roughly 2.8% average growth of Labs plus Immunohematology in 2023 to 2025, and is credited because those businesses run on multi-year reagent contracts with minimum purchases; it is netted against continued declines in Point of Care and donor screening. For year one, owner earnings and business cash flow per share improved in 2025 compared with 2024, so a fall to $0.50 sits below the trailing trend rather than above it. Worth of the business is about $17 per share (about $1.2 billion); obligations are $44 per share (about $3.0 billion); the shortfall is about $27 per share. In plain terms, the company appears to owe more than the business is worth on the evidence available today. Bull case (about negative $2 per share). The merger integration was declared complete at the end of 2025 (it cost $113 million in 2023, $127 million in 2024 and $89 million in 2025) and the restructuring programme is capped at roughly $100 million through 2027. If both really end, business cash flow rises to about $2.27 per share (the 2025 level plus the roll-off of integration cost) by 2028 and grows 3% a year to 2035. Worth of the business is about $42 per share (about $2.9 billion); obligations are $44; the difference is about negative $2. Even when everything identified goes right, the shares are worth roughly nothing on this evidence. We do not credit the LEX Diagnostics point-of-care molecular platform, a rebound in Point of Care volume, the announced cost-reduction targets, or China or other regional recoveries, because none is contracted or already demonstrated. The company has also ended development of its Savanna molecular platform (June 2025), so no return is credited from it. Bear case (about negative $44 per share). Business cash flow starts at $0.20 per share and shrinks about 10% a year as Point of Care and donor screening keep declining and interest costs bite (interest expense was $105.8 million in the first half of 2026 versus $80.5 million a year earlier). Business worth is only about $1 per share (about $85 million) against about $46 per share of obligations. At roughly 4.7 times our estimate of 2025 earnings before interest, tax, depreciation and one-time charges, net debt leaves little cushion under the 4.5 times leverage covenant (which uses a more generous, company-defined earnings measure); a breach would likely force an amendment on worse terms, asset sales, dilution or a restructuring that leaves shareholders little or nothing. Securities class actions over past COVID-test sales and the Savanna filing add unquantified risk. What would make this wrong. If instrument build costs are lower than we infer, or if the roughly $150 million a year of integration and restructuring cash costs truly end and margins hold, business cash flow could reach $2.50 to $4.00 per share and the equity would have real value; treating the whole inventory outflow as timing (the alternative reading) would put owner earnings near zero in 2025 and business cash flow near $2.50 per share, which is why the margin-of-safety price is tied to a business trigger. Points we could not fully reconcile: we could not find text explanation for why first-half 2026 operating cash flow before working capital fell to about $59 million from about $139 million a year earlier, and the price and terms of the LEX Diagnostics transaction are not disclosed in the annual report, so we relied on the reported June 2026 debt and acquisition payment. We also removed the $25.4 million cash tax refund received in 2025 from the level we used as normal.